Patient Satisfaction And Disease Control In Patients With Systemic Lupus Erythematosus Is Not Affected By Switching From Intravenous Belimumab To Subcutaneous Injections

PURPOSE: Since the launch of belimumab in 2011, the BLyS antibody has been increasingly used in the therapy of systemic Lupus erythematosus (SLE). Comparative studies showed that the intravenous (i.v.) and subcutaneous (s.c.) administration forms do not differ in their efficacy. Since the approval o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mucke, Johanna, Brinks, Ralph, Fischer-Betz, Rebecca, Richter, Jutta G, Sander, Oliver, Schneider, Matthias, Chehab, Gamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839583/
https://www.ncbi.nlm.nih.gov/pubmed/31806937
http://dx.doi.org/10.2147/PPA.S227208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839583/
https://www.ncbi.nlm.nih.gov/pubmed/31806937
http://dx.doi.org/10.2147/PPA.S227208

Ejemplares similares